ArriVent BioPharma (AVBP) Institutional Ownership $27.45 +0.86 (+3.23%) (As of 11/22/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for ArriVent BioPharma (NASDAQ:AVBP)CurrentInstitutional OwnershipPercentage9.48%Number ofInstitutional Buyers(last 12 months)20TotalInstitutional Inflows(last 12 months)$131.99MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$1.78M Get AVBP Insider Trade Alerts Want to know when executives and insiders are buying or selling ArriVent BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data AVBP Institutional Buying and Selling by Quarter Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. ArriVent BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC41,522$976K0.0%+1,124.8%0.123% 11/16/2024 Geode Capital Management LLC597,165$14.04M0.0%+154.2%1.778% 11/15/2024 Barclays PLC41,522$976K0.0%+1,124.8%0.124% 11/15/2024 Jane Street Group LLC10,626$250K0.0%-30.7%0.032% 11/15/2024 State Street Corp476,809$11.21M0.0%+210.4%1.419% 11/14/2024 Suvretta Capital Management LLC1,845,162$43.36M1.4%+7.7%5.493% Get the Latest News and Ratings for AVBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. 11/14/2024 MetLife Investment Management LLC16,350$384K0.0%+168.9%0.049% 11/13/2024 BNP Paribas Financial Markets21,965$516K0.0%+32.6%0.065% 11/13/2024 FMR LLC2,119,695$49.81M0.0%+8.7%6.310% 11/13/2024 The Manufacturers Life Insurance Company 10,234$240K0.0%N/A0.030% 11/12/2024 Charles Schwab Investment Management Inc.202,368$4.76M0.0%+153.8%0.602% 10/30/2024 AlphaCentric Advisors LLC15,000$352K0.3%-82.6%0.045% 10/24/2024 Novo Holdings A S1,505,315$35.38M1.8%+0.4%4.494% 10/3/2024 SG Americas Securities LLC11,927$280K0.0%N/A0.036% 8/20/2024 Novo Holdings A S1,500,000$27.83M1.4%+39.3%4.478% 8/1/2024 Rhumbline Advisers12,707$236K0.0%+30.1%0.038% 7/26/2024 Bank of New York Mellon Corp29,847$554K0.0%+31.4%0.089% 7/26/2024 AlphaCentric Advisors LLC86,000$1.60M1.2%+3.6%0.257% 5/24/2024 Farallon Capital Management LLC151,768$2.71M0.0%N/A0.453% 5/16/2024 Blackstone Inc.25,000$446K0.0%N/A0.075% 5/15/2024 Hhlr Advisors LTD.3,929,117$70.17M1.5%N/A11.732% 5/15/2024 Altitude Crest Partners Inc.555,555$9.92M4.2%N/A1.659% 5/14/2024 American International Group Inc.4,845$87K0.0%N/A0.014% 5/10/2024 Vanguard Group Inc.648,735$11.59M0.0%N/A1.937% 5/1/2024 BNP Paribas Financial Markets4,659$83K0.0%N/A0.014% (Data available from 1/1/2016 forward) AVBP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AVBP shares? During the previous two years, 21 institutional investors and hedge funds held shares of ArriVent BioPharma. The most heavily invested institutionals were Hhlr Advisors LTD. ($70.17M), FMR LLC ($49.81M), Suvretta Capital Management LLC ($43.36M), Novo Holdings A S ($35.38M), Geode Capital Management LLC ($14.04M), Vanguard Group Inc. ($11.59M), and State Street Corp ($11.21M).Learn more on AVBP's institutional investors. What percentage of ArriVent BioPharma stock is owned by institutional investors? 9.48% of ArriVent BioPharma stock is owned by institutional investors. Learn more on AVBP's institutional investor holdings. Which institutional investors have been buying ArriVent BioPharma stock? Of the 20 institutional investors that purchased ArriVent BioPharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Hhlr Advisors LTD. ($3.93M), Vanguard Group Inc. ($648.74K), Altitude Crest Partners Inc. ($555.56K), Novo Holdings A S ($428.18K), Geode Capital Management LLC ($362.22K), State Street Corp ($323.19K), and FMR LLC ($169.51K). How much institutional buying is happening at ArriVent BioPharma? Institutional investors have bought a total of 6,985,048 shares in the last 24 months. This purchase volume represents approximately $131.99M in transactions. Which ArriVent BioPharma major shareholders have been selling company stock? The following institutional investors have sold ArriVent BioPharma stock in the last 24 months: AlphaCentric Advisors LLC ($71K), and Jane Street Group LLC ($4.71K). How much institutional selling is happening at ArriVent BioPharma? Institutional investors have sold a total of 75,707 shares in the last 24 months. This volume of shares sold represents approximately $1.78M in transactions. Related Companies ImmunityBio Institutional Ownership Apellis Pharmaceuticals Institutional Ownership MoonLake Immunotherapeutics Institutional Ownership PTC Therapeutics Institutional Ownership Agios Pharmaceuticals Institutional Ownership HUTCHMED Institutional Ownership Merus Institutional Ownership Xenon Pharmaceuticals Institutional Ownership Edgewise Therapeutics Institutional Ownership Verona Pharma Institutional Ownership This page (NASDAQ:AVBP) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
